Company / EPS (Diluted)
UroGen Pharma Ltd. EPS (Diluted) History
FY2018-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.90
FY2021
5-year range
-$5.90 / -$5.90
FY2018-FY2021
Trend
-15.2%
vs FY2020
Sector context
#186 of 204
Health Care
What the data says
Among 204 Health Care companies, UroGen Pharma Ltd. is in the bottom 9% for eps (diluted). EPS (Diluted) has declined for 3 consecutive years, from $-1.91 in FY2018 to $-5.90 in FY2021.
Based on SEC 10-K filings.
-5.90 in FY2021.
Declined from $-2.14 to $-5.90 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 204This company -$5.90 Sector average -$0.89
▼
-565.7% below sector average
Key checks
Key Insights
- UroGen Pharma Ltd.'s eps (diluted) has declined for 3 consecutive years.
- In FY2021, eps (diluted) decreased 15.2% year-over-year.
- Ranks #186 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -$5.90 | -15.2% |
| FY2020 | -$5.12 | -139.3% |
| FY2019 | -$2.14 | -12.0% |
| FY2018 | -$1.91 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026